Aravive (STU:VE11) Interest Expense : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Aravive Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aravive's interest expense for the three months ended in Sep. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aravive's Operating Income for the three months ended in Sep. 2023 was € -8.35 Mil. Aravive's Interest Expense for the three months ended in Sep. 2023 was € 0.00 Mil. GuruFocus does not calculate Aravive's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aravive Interest Expense Historical Data

The historical data trend for Aravive's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Interest Expense Chart

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-2.14

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Aravive Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Aravive (STU:VE11) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aravive's Interest Expense for the three months ended in Sep. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was €-8.35 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was €0.29 Mil.

Aravive's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

GuruFocus does not calculate Aravive's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Aravive Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive Headlines

No Headlines